562 related articles for article (PubMed ID: 28277287)
1. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
7. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
8. The many faces of Janus kinase.
Seavey MM; Dobrzanski P
Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
[TBL] [Abstract][Full Text] [Related]
9. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
10. A potential role of ruxolitinib in leukemia.
Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
[TBL] [Abstract][Full Text] [Related]
11. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Bose P; Verstovsek S
J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
[TBL] [Abstract][Full Text] [Related]
13. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
15. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
16. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Atallah E; Verstovsek S
Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Barrio S; Gallardo M; Arenas A; Ayala R; Rapado I; Rueda D; Jiménez-Ubieto A; Albizua E; Burgaleta C; Gilsanz F; Martinez-Lopez J
Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
[TBL] [Abstract][Full Text] [Related]
18. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Loscocco GG; Vannucchi AM
Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Mesa RA
IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
[TBL] [Abstract][Full Text] [Related]
20. [Targeted therapy of polycytemia vera patients].
Shikhbabaeva DI; Shuvaev VA; Martynkevich IS; Zyuzgin IS; Abdulkadyrov KM
Vopr Onkol; 2016; 62(4):386-93. PubMed ID: 30474944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]